Brief: Grand Pharmaceutical Says STC3141 Approved By NMPA To Conduct Phase II Clinical Study In China
17/07/2023 11:23
July 17 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* STC3141 WAS APPROVED BY NMPA TO CONDUCT PHASE II CLINICAL
STUDY
IN CHINA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement